Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation
CAMBRIDGE, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Agios Pharmac...